前沿生物：2025年前三季度净利润约-1.60亿元

Group 1 - The core viewpoint of the article highlights Frontier Bio's financial performance in Q3 2023, showing a revenue increase but a significant net loss [1] - Frontier Bio reported revenue of approximately 103 million yuan for the first three quarters of 2025, representing a year-on-year increase of 12.8% [1] - The net profit attributable to shareholders was a loss of approximately 160 million yuan, with basic earnings per share reflecting a loss of 0.43 yuan [1] Group 2 - As of the report, Frontier Bio's market capitalization stands at 5.4 billion yuan [1]